The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting

AIM: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK. METHODS: A Microsoft Excel model was used to evaluate the cost‐utility of IDegLira versus BBT over...

Descripción completa

Detalles Bibliográficos
Autores principales: Drummond, Russell, Malkin, Samuel, Du Preez, Michelle, Lee, Xin Ying, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175071/
https://www.ncbi.nlm.nih.gov/pubmed/29797389
http://dx.doi.org/10.1111/dom.13375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175071/
https://www.ncbi.nlm.nih.gov/pubmed/29797389
http://dx.doi.org/10.1111/dom.13375

Ejemplares similares